These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 3548266

  • 1. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW, Alberts MJ.
    Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
    [No Abstract] [Full Text] [Related]

  • 2. Parallel double-blind study of pergolide in Parkinson's disease.
    Jankovic J, Orman J.
    Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265
    [No Abstract] [Full Text] [Related]

  • 3. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, Shoulson I, Kurlan R, Grimes JD, Jankovic J.
    Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
    [Abstract] [Full Text] [Related]

  • 4. Sinemet CR in Parkinson's disease.
    Pfeiffer RF, Wilken KE, Glaeske CS, Hofman R.
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [Abstract] [Full Text] [Related]

  • 5. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S.
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [Abstract] [Full Text] [Related]

  • 6. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M, Riopelle R, Libman I, Bouchard S.
    Adv Neurol; 1987 Nov; 45():535-8. PubMed ID: 3548263
    [No Abstract] [Full Text] [Related]

  • 7. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
    Feldman RG, Mosbach PA, Kelly MR, Thomas CA, Saint Hilaire MH.
    Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J.
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [Abstract] [Full Text] [Related]

  • 13. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH, Sage JI.
    Ann Clin Lab Sci; 1989 Nov; 19(2):101-6. PubMed ID: 2665626
    [Abstract] [Full Text] [Related]

  • 14. Sinemet in Parkinson's disease: efficacy with and without food.
    Bozek CB, Suchowersky O, Purves S, Calne S, Calne DB.
    Clin Neuropharmacol; 1986 Nov; 9(2):196-9. PubMed ID: 3708604
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Drug therapy of Parkinson's disease].
    Zhou XD.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):193-6. PubMed ID: 4075905
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
    Aarli JA, Gilhus NE.
    Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.